Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989–2003

M van Blankenstein*,1, CWN Looman2, PD Siersema1, EJ Kuipers1 and JWW Coebergh2,3
1Department of Gastroenterology and Hepatology, Erasmus MC, Erasmus University Medical Centre, Rotterdam, The Netherlands; 2Department of Public Health, Erasmus MC, Erasmus University Medical Centre, Rotterdam, The Netherlands; 3Comprehensive Cancer Centre South, Integraal Kankercentrum Zuid, Eindhoven, The Netherlands

Over the 15-year period 1989–2003, the incidence of oesophagus–cardia adenocarcinoma in the Netherlands rose annually by 2.6% for males and 1.2% for females. This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus (ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of more than 1% for both genders. Nonlinear cohort patterns were found in females with ACO and for both genders in AGC; a nonlinear period pattern was observed only in males with AGC. These differing epidemiological patterns for ACO and AGC do not support a common aetiology. Proposed underlying factors for the rise in ACO incidence appear to have little effect on AGC incidence. This and the secular decline in smoking among males may have led to the decline in AGC incidence.

Keywords: epidemiological trends; adenocarcinoma of the oesophagus; adenocarcinoma of the cardia; Barrett’s oesophagus; age–period–cohort pattern analysis

Over the past 30 years, the incidence of adenocarcinoma of the oesophagus (ACO) has gradually exceeded that of squamous cell carcinoma (Heitmiller and Sharma, 1996). The recognition that in the oesophagus, adenocarcinomas can (Morson and Belcher, 1952; Naef et al., 1975) and mainly do (Haggitt et al., 1978) develop in a columnar-lined (Barrett’s) oesophagus has underlined the necessity of distinguishing between these adenocarcinomas (ACO) and the adenocarcinomas of the gastric cardia (AGC), which do not originate in the oesophagus. Where this distinction is not made, we employ the term oesophagus–cardia adenocarcinoma. A steady rise in the incidence rates of the oesophagus–cardia adenocarcinoma has been reported from the United States and Europe (Bollschweiler et al., 2001; El-Serag, 2002). However, whether this rise involved both ACO and AGC to the same extent has remained unclear, as most registries did not distinguish them. This is not surprising because, even for pathologists examining resected specimens, the distinction is often problematic (Siewert and Stein, 1998; Driessen et al., 2003). In Denmark, in the period 1989–1995, an AGC to ACO incidence ratio of 1.8–1 in males was reported (Eurocim, 2001); a panel of experts reviewing the original clinical data reversed this ratio to 1–2.4 (van Blankenstein et al., 2005). The Netherlands is among those countries that have the highest incidence rates of both ACO and AGC (Corley and Buffle, 2001).

By analysing the differential time trends in ACO and AGC incidence over a 15-year period and examining their age-cohort-period patterns, we have estimated their respective contributions to the rising incidence of the oesophagus–cardia adenocarcinoma in the Netherlands.

MATERIALS AND METHODS

The Netherlands, a country of 16 million inhabitants, has nine Regional Cancer Registries, hosted by the regional Comprehensive Cancer Centres, to which both hospital medical record departments and pathology departments report all malignancies. The Netherlands Cancer Registry in turn collates these data. The ascertainment of symptomatic oesophageal cancer in the Netherlands is likely to be high, as it practically always results in endoscopic and histological diagnosis for curative or palliative interventions (Siersema et al., 2005).

For the 15-year period 1989–2003, the Netherlands Cancer Registry provided annual age- and gender-specific incidence data for ACO (the combined data for ICD.O regions C.15.3, C15.4, C15.5 and C15.9) and for AGC (ICD.O region C.16.0), both ICD.O morphology 8140/3 by 3-year age groups. This allowed estimation of time trends and age–period–cohort analysis for each cancer by log-linear Poisson regression models. Incidence rates were also provided as European standardised rates (ESR) by 5-year age groups. In addition, ACO incidence data by 5-year age groups were provided separately for each of the three levels of the oesophagus, upper-, middle- and lower-third and unspecified (ICD.O regions C.15.3, C15.4, C15.5 and C15.9).

For the cohort models, a mean year of birth was calculated for each 3-year age group. The estimated drift parameters constituted
We did observe an unexpected similarity between both genders in the numbers of cases of ACO at the upper- and the middle-third. This was the result of a surge in the number of ACO cases in females over 75 years; upper-third: males 18 (ESR 0.44), females 53 (ESR 0.65); and middle-third: males 146 (ESR 2.6), females 206 (ESR 2.5).

The age- and gender-specific annual increases in ACO incidence are presented in Table 2. These increases were highest in the 40–60-year age group, decreasing significantly for both genders at ages 61–84 (P = 0.03). However, in males this decrease amounted to only 25% against 62% in females. Consequently, the 1.2:1 male/female ratio at ages 40–60 rose to 2.3:1 at ages 61–84, finally resulting in annual rates of increase of 7.2% for males and 3.5% for females.

### RESULTS

**Incidence (ESR) and trends by log-linear regression models**

Over the 15-year period 1989–2003, ESR of oesophagus–cardia adenocarcinoma rose by 34% (from $7.4 \times 10^5$ to $10.0 \times 10^5$) in males, by 25% (from $1.7 \times 10^5$ to $2.1 \times 10^5$) in females and by $33\%$ (from $9.1 \times 10^5$ to $12.1 \times 10^5$) for both combined.

The ESR and time trends for ACO and AGC by gender for these years are shown in Figure 1. The mean ESR of the two tumours over the total 15-year period was practically identical, for ACO, $4.3 \times 10^5$ in men and $0.96 \times 10^5$ in females and for AGC, $4.3 \times 10^5$ in males and $0.92 \times 10^5$ in females. Initially, male AGC incidence was far in excess of that of ACO. However, from 1998 onwards, the combination of steeply rising ACO incidence and a downward AGC trend reversed this relationship. A similar, but less pronounced, pattern was seen in females. The incidence trends, after correction for age, for both genders over the 15-year period 1989–2003 are shown in Table 1. Annual AGC incidence declined by $-1.7\%$ in males ($P = 0.0002$) and $-1.2\%$ in females ($P = 0.05$). In contrast, ACO incidence increased by $7.2\%$ p.a. ($P < 0.001$) for men but only $3.5\%$ p.a. ($P = 0.006$) for females. Table 1 also presents the trends in ACO incidence at three levels of the oesophagus. In males, these increases were: upper-third, $8.9\%$ p.a.; middle-third, $6.5\%$ p.a. and lower-third, $8.8\%$ p.a. ($P < 0.0001$ for each, with no significant differences between the three levels). In females, there were no significant annual increases at the upper- and middle-third, but, at the lower-third, an annual increase of $6.1\%$ was found, $P < 0.0001$. In 458 of 6538 cases of ACO (7%), no level was specified, with no discernable trends.

### Age-period–cohort models

The results of the cohort and period estimates are shown in Table 3. For each tumour, the mean changes in the annual incidence for each of three periods (before 1926, 1926–1944 and after 1944) were differentiated by year of birth for cohort effects and by incidence year for period effects. Significant differences

| Year | 1989 | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| ESR  | 4.3  | 4.4  | 4.5  | 4.5  | 4.6  | 4.6  | 4.7  | 4.8  | 4.9  | 5.0  | 5.1  | 5.2  | 5.3  | 5.4  | 5.5  |

---

**Table 1** Per annum percentage changes in the incidence rates of adenocarcinoma of the oesophagus, overall and by level, and of the cardia. Cancer Research UK. The Netherlands: Cancer Registry.
between the values for the three periods indicated a nonlinear cohort or period effect.

There were no significant nonlinear cohort or period effects in males with ACO. In contrast, females with ACO showed a significant nonlinear cohort effect ($P = 0.006$), with the greatest increase in the 1926–44 cohorts, but here again, there was no significant period effect ($P = 0.64$).

For AGC, a nonlinear cohort effect was found in males, $P < 0.0002$, demonstrating a steadily declining trend in cohorts born after 1926. This was in contrast to the nonlinear cohort effect in females, $P = 0.01$, which demonstrated a rising trend in cohorts born after World War II. Finally, for AGC a nonlinear period effect in males, $P = 0.0001$ (Figure 2), partly mirrored in females, $P = 0.3$, suggested a decline caused by a period effect setting in around 1995.

**DISCUSSION**

These results from the Netherlands confirm the worldwide trend for increasing incidence of oesophagus–cardia adenocarcinoma (Rollschweiler et al., 2001; El-Serag, 2002). While in the Netherlands, this rising trend was very pronounced for ACO, the AGC incidence rates actually declined for both genders. Our major finding is that, at least in the Netherlands, the rising incidence of oesophagus–cardia adenocarcinoma over the past 15 years was entirely due to ACO, which, despite their clinical similarity, points to aetiological differences (Wijnhoven et al., 1999).

In the years 1968–1994, AGC incidence was already declining in the Netherlands (Laheij et al., 1999). However, where previously (ICD 9) visible Barrett’s oesophagus was considered desirable for the diagnosis of ACO, current practice is to be guided by localisation of the major bulk of the tumour (Bytzer et al., 1999; Driessen et al., 2003). This revision could have resulted in a diagnostic shift from AGC to ACO, thereby explaining the period effect observed in the declining AGC incidence. However, in males this is contradicted on two grounds: (1) by the identical rising trends in the incidence of ACO localised in the upper- and middle-third of the oesophagus to that observed in the lower-third (Table 1). While misclassification in the lower-third might well have caused a diagnostic shift from AGC to ACO, this would obviously have been extremely unlikely for the upper- and middle-third. Since a diagnostic shift limited to females is unlikely, the absence of these trends in females hardly weighs against this argument. (2) A diagnostic shift of a size sufficient to explain the observed downward period effect in AGC incidence should have been reflected in a complementary upward period effect in ACO, which, however, was not observed (Figure 2). We therefore consider both the rising ACO incidence and the declining AGC incidence to be genuine.

There was no significant nonlinear male ACO cohort effect, meaning that the annual changes in ACO incidence did not differ significantly by year of birth (Table 3). However, the annual increases were considerable, amounting to over 9% in the youngest age cohorts. In the absence of factors causing a period effect, such as a major change in tumour classification or the appearance of a new carcinogen, and because of the presence of a cohort effect in females, we are convinced of a cohort effect in males with ACO, thus confirming the cohort effect for ACO found in US SEER-data (El-Serag et al., 2002).

The two-fold gender differences in the annual percentage increases in ACO incidence (Table 1) were surprising, as the annual incidence increase in Barrett’s oesophagus in the Netherlands was recently demonstrated to be equal for both genders (van Soest et al., 2005). However, the source of this gender difference was revealed to be a steep dip in the annual increase in AGC incidence for females, and to a far smaller extent in males, aged 61–84, that is those born between 1905 and 1940 (Table 2). This dip was not a temporary phenomenon as the increases at ages 40–85+ were calculated separately for each of the 15 years. We suggest nonsteroidal anti-inflammatory drug (NSAID) use by the elderly as a possible cause of this dip. Several studies have suggested a protective effect of NSAIDs against ACO in patients with Barrett’s oesophagus (Souza et al., 2000; Buttar et al., 2002; Kaur et al., 2002; Bardou et al., 2004; Gammon et al., 2004; Tsibouris et al., 2004; Vaughan et al., 2005). In addition, there are marked gender differences in NSAID use in the elderly (Schnitzer et al., 2001; Helin-Salmivaara et al., 2003). In the Netherlands, the Integrated Primary Care Information electronic database covering 500,000 patients revealed the NSAID user rate, rising from 10% in 1989 to 14% in 2003.

**Table 2** The per annum percentage increase in the incidence rates of adenocarcinoma of the oesophagus by age and gender

| Age bands | 40–60 | 61–66 | 67–72 | 73–78 | 79–84 | 85+ |
|-----------|-------|-------|-------|-------|-------|-----|
| Males     | 9.0   | 5.9   | 6.0   | 7.0   | 7.8   | 5.5 |
| Females   | 7.5   | 4.8   | 3.6   | 0.6   | 2.5   | 4.3 |

Drift = per annum percentage change.

**Table 3** Cohort or period effects for adenocarcinoma of the oesophagus (ACO) and the gastric cardia (AGC) by gender 1989–2003

| Tumour | Gender | Drift  | < 1926 | 1926–44 | > 1944 | P-value |
|--------|--------|--------|--------|---------|--------|---------|
|        |        |        | 1989–93| 1994–99| 1999–03| P-value |
| ACO    | Males  | +7.2   | +7.2   | +7.1   | +9.1   | 0.08    |
|        | Females| +3.5   | +2.1   | +7.1   | +4.0   | 0.006   |
| AGC    | Males  | −1.7   | +0.1   | −3.0   | −3.1   | <0.0002 |
|        | Females| −1.2   | −2.6   | +0.1   | +4.1   | 0.01    |

Epidemiology
below 45 to 23% over 45 years and a 1.5-fold higher user rate in females (Dr MCJM Sturkenboom, personal communication). In individuals over the age of 61 with Barrett’s oesophagus, NSAID use, by postponing or preventing the onset of ACO, is likely to have contributed to the reduction in the annual rise of ACO incidence, this effect being more marked in females, consistent with their higher NSAID consumption.

The declining AGC incidence raises questions about the nature of AGC and its aetiology. The most commonly used Sievert classification defines AGC as an adenocarcinoma with its centre 5 cm proximal or distal from the anatomical cardia and distinguishes it into three types. Type I arising from (short segment) Barrett’s oesophagus and therefore, in our opinion, ACO; type II, true AGC, arising from the cardiac epithelium or a short segment of intestinal metaplasia at the oesophagogastric junction; and type III, subcardial gastric cancer, infiltrating the cardia from below (Siewert and Stein, 1998). Since it has been suggested that there are two types, one related to *Helicobacter pylori* below (Siewert and Stein, 1998). Since it has been suggested that there are two types, one related to *Helicobacter pylori* infection and Barrett’s oesophagus (Souza and Spechler, 2005), these factors appear less relevant for AGC, as demonstrated by a recent meta-analysis of overweight as a risk factor for gastro-oesophageal reflux disease, which, in marked contrast to ACO, found only a marginally increased risk of AGC from obesity (Hampel *et al.*, 2005). Studies of *H pylori* infection in AGC also failed to find a significant relationship (Hansen *et al.*, 1999; Wu *et al.*, 2003; Gulmann *et al.*, 2004).

Smoking, however, may well be important in the aetiology of AGC. In a prospective study with accurate differentiation between ACO and AGC, AGC was found to be dose-dependent related to smoking, odds ratio 4.2, whereas the relation with ACO was weak or absent (Lagergren *et al.*, 2000). A complementary observation was made in institutionalised intellectually disabled individuals who do not smoke (van Blankenstein *et al.*, 2004).

The contrasting AGC cohort effects in males and females (Figure 3) nicely fit the contrasting secular changes in smoking patterns in Dutch men and women, as implied by a lung cancer study, which found a steady decline in the number of male smokers born after 1914. This is in contrast to females, in whom, since the second half of the 19th century and in successive birth cohorts, the number of smokers has steadily increased and, after a relative plateau between 1928–37, has continued to increase, with numbers doubling in 1945 and later birth cohorts (Barendregt *et al.*, 2002). The net decline in the AGC incidence is explained by the 4:1 male/female ratio, with the impact of the declining numbers of male smokers considerably outweighing that of the rising number of their female counterparts. We suggest that these findings lend support to a significant role for smoking in the aetiology of AGC.

Finally, the conversion of nitrite in saliva by acid into potentially mutagenic substances such as nitrous acid, nitratosive species and nitric oxide comprises a less well-established aetiology for the oesophagus–cardia adenocarcinoma which may have gained importance by the greater use of nitrogenous fertilizers after World War II (Spechler, 2002). In patients with Barrett’s oesophagus, mutagenic nitrite conversion has recently been shown to occur within the Barrett’s oesophagus segments (Suzuki *et al.*, 2005). For AGC, this conversion is therefore likely to be localised in the cardia (McColl, 2005). Whether this hypothetical factor is still on the increase or has passed its peak is unknown.

**REFERENCES**

Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. *Clin Gastroenterol Hepatol* 2: 880–887

Barendregt JJ, Looman CW, Bronnum-Hansen H (2002) Comparison of cohort smoking intensities in Denmark and the Netherlands. *Bull World Health Organ* 80: 26–32

Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. *Cancer* 92: 549–555

Buttar NS, Wang KK, Leontovich O, Westcott JJ, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. *Gastroenterology* 122: 1101–1112

Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N (1999) Models for temporal variation in cancer rates. I: age-period and age-cohort models. *Stat Med* 6: 449–467

Clayton D, Schiffrers E (1987b) Models for temporal variation in cancer rates. II: age-period-cohort models. *Stat Med* 6: 469–481

Corley DA, Buñol PA (2001) Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in five Continents database. *Int J Epidemiol* 30: 1415–1425

Driessen A, Van Raemdonck D, De Leyn P, Filez L, Peeters M, Winnepenninckx V, Penninckx F, Lerut T, Ectors N (2003) Are carcinomas of the cardia oesophageal or gastric adenocarcinoma? *Eur J Cancer* 39: 2487–2494

El-Serag HB (2002) The epidemic of esophageal adenocarcinoma. *Gastroenterol Clin N Am* 31: 421–440, viii

El-Serag HB, Kvipil P, Hacken-Bitar J, Kramer JR (2005) Abdominal obesity and the risk of Barrett’s oesophagus. *Am J Gastroenterol* 100: 2151–2156

El-Serag HB, Mason AG, Petersen N, Key CR (2002) Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. *Gut* 50: 368–372

Eurocim v. 4.0 (2001) European incidence database V2.3, ICD-10 dictionary (2001). Lyon: European Network of Cancer Registries
Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni Jr JF, Weinstein IB, Hibshoosh H (2004) Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. *Cancer Epidemiol Biomarkers Prev* 13: 34–39

Gulmann C, Rathore O, Grace A, Hegarty H, O’Grady A, Leader M, Patchett S, Kay E (2004) Cardiac-type (mucinous) mucosa and carditis are both associated with *Helicobacter pylori*-related gastritis. *Europ J Gastroenterol Hepatol* 16: 69–74

Haggitt RC, Tryzelaar J, Ellis FH, Colcher H (1978) Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. *Am J Clin Pathol* 70: 1–5

Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med* 143: 199–211

Hansen S, Melby KK, Aase S, Jellum E, Vollset SE (1999) *Helicobacter pylori* infection and risk of curda cancer and non-cardia gastric cancer. A nested case–control study. *Scand J Gastroenterol* 34: 353–360

Heitmiller RF, Sharma RR (1996) Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. *J Thorac Cardiovasc Surg* 112: 130–136

Helin-Salminavaara A, Klaucka T, Huupponen R (2003) Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. *Eur J Clin Pharmacol* 59: 477–482

Kaur BS, Khamnehei N, Iravani M, Namburut SS, Lin O, Triadafilopoulos G (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett’s esophageus. *Gastroenterology* 123: 60–67

Lagergren J, Bergstrom R, Lindgren A, Nyren O (2000) The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. *Int J Cancer* 85: 340–346

Laheij RJ, Straatman H, Verbeek AL, Jansen JB (1999) Mortality trend of cancer of the gastric cardia in The Netherlands, 1969–1999. *Int J Epidemiol* 28: 391–395

McColl KE (2005) When saliva meets acid: chemical warfare at the gastroesophageal junction. *Gut* 54: 1–3

McColl KE (2006) Cancer of the gastric cardia. *Best Pract Res Clin Gastroenterol* 20: 687–696

Morson BC, Belcher JR (1952) Adenocarcinoma of the esophagus and ectopic gastric mucosa. *Br J Cancer* 6: 127

Naef AP, Savary M, Ozzello L (1975) Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. *J Thorac Cardiovasc Surg* 70: 826–835

Richter JE, Falk GW, Vaezi MF (1998) *Helicobacter pylori* and gastro-esophageal reflux disease: the bug may not be all bad. *Am J Gastroenterol* 93: 1800–1802

Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meeuwsen SG, van Kamp GJ, Vandenbroucke-Grauls CM (1997) *Helicobacter pylori* and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. *Am J Gastroenterol* 92: 1480–1482

Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ (2001) Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. *Clin Ther* 23: 1984–1998

Siersma PD, Verschuur EM, Homs MY, van der Gaast A, Eijkenboom WM, Kuipers EJ (2005) [Palliative treatment in patients with oesophagus carcinoma]. *Ned Tijdschr Geneesk* 149: 2775–2782

Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesopahogastic junction. *Br J Surg* 85: 1457–1459

Souza RF, Shewmake K, Beer DG, Cayer B, Spechler SJ (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. *Cancer Res* 60: 5767–5772

Souza RF, Spechler SJ (2005) Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. *CA Cancer J Clin* 55: 334–351

Spechler SJ (2002) Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. *Gastroenterology* 122: 1518–1520

Suzuki H, Iijima K, Scobie G, Pyfe V, McColl KE (2005) Nitrate and nitrosative chemistry within Barrett’s oesophagus during acid reflux. *Gut* 54: 1527–1535

Tsibouris P, Hendrickse MT, Isaacs PE (2004) Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett’s oesophagus who develop an oesophageal adenocarcinoma. *Aliment Pharmacol Ther* 20: 645–655

van Blankenstein M, Bohmer CJ, Hop WC (2004) The incidence of adenocarcinoma in Barrett’s esophagus in an institutionalized population. *Europ J Gastroenterol Hepatol* 16: 903–909

van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P (2005) The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s esophagus makes a difference. *Am J Gastroenterol* 100: 766–774

van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ (2005) Increasing incidence of Barrett’s oesophagus in the general population. *Gut* 54: 1062–1066

Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. *Lancer Oncol* 6: 945–952

Visscher TL, Kromhout D, Seidell JC (2002) Long-term and recent time trends in the prevalence of obesity among Dutch men and women. *Int J Obes Relat Metab Disord* 26: 1218–1224

Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW (1999) Adenocarcinomas of the distal esophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. *Br J Surg* 86: 529–535

Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D (2003) Role of *Helicobacter pylori* CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. *Int J Cancer* 103: 815–821